Welcome to our dedicated page for Macrogenics SEC filings (Ticker: MGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MacroGenics, Inc. (MGNX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. MacroGenics states that it is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer, and its filings offer additional detail on this business through formal reports.
Recent Forms 8‑K filed by MacroGenics include items on quarterly financial and operating results, as well as leadership changes. For example, the company has filed current reports describing results of operations and financial condition for specific quarters and announcing the appointment of a new President and Chief Executive Officer. Another Form 8‑K discloses the planned departure of the Senior Vice President, Clinical Development and Chief Medical Officer and notes interim oversight arrangements for clinical development.
Through this page, users can review MacroGenics’ current reports alongside other SEC documents such as annual and quarterly reports when available. These filings often reference press releases that discuss clinical programs like lorigerlimab, antibody-drug conjugate candidates MGC026, MGC028 and MGC030, and partnered programs including MGD024, ZYNYZ® and TZIELD®, as well as collaboration and royalty structures described by the company.
Stock Titan enhances access to these materials with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the main topics in MacroGenics’ disclosures. Investors researching MGNX can use this page to follow official information on financial performance, executive transitions, material agreements and other events that MacroGenics reports to regulators.
MacroGenics Inc: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A, stating it beneficially owns 0 shares of MacroGenics common stock, equal to 0% of the class.
The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report holdings separately; Vanguard states those entities pursue the same investment strategies previously followed.
MacroGenics, Inc. reported 2025 results and outlined key pipeline milestones. Total revenue was $149.5 million, essentially flat with 2024, while a shift toward contract manufacturing drove contract manufacturing revenue up to $52.6 million from $13.1 million.
Research and development expenses fell to $147.2 million and selling, general and administrative costs dropped to $39.2 million, reflecting program pruning and lower stock-based compensation. Net loss widened slightly to $74.6 million, in part because 2024 benefited from a gain on the sale of MARGENZA.
Cash, cash equivalents and marketable securities totaled $189.9 million as of December 31, 2025, and the company projects cash runway into late 2027. MacroGenics highlighted upcoming data: initial Phase 1 results for ADCs MGC026 and MGC028 in 2026, a mid-2026 update from the lorigerlimab LINNET study currently under a partial FDA clinical hold, and a planned third-quarter 2026 IND filing for ADC MGC030. It also noted substantial potential partner milestones tied to programs with Gilead, Sanofi and Incyte.
MacroGenics, Inc. outlines its oncology-focused business, pipeline and key partnerships in this annual report. The company develops antibody-based cancer therapeutics, including antibody-drug conjugates and multi-specific antibodies generated from its DART and TRIDENT platforms, and operates a commercial-scale cGMP manufacturing facility in Maryland.
MacroGenics has contributed three FDA-approved medicines now marketed by partners and reports over $1.6 billion in cumulative non-dilutive collaboration funding since inception. It details clinical progress for wholly owned candidates MGC026, MGC028 and lorigerlimab, as well as partnered CD123×CD3 DART MGD024 with Gilead. The report also highlights sizeable milestone inflows and royalty monetizations tied to TZIELD and ZYNYZ, new manufacturing and supply agreements, and explains major risks, including funding needs, strong competition and recent safety-related setbacks such as a partial FDA clinical hold on the LINNET study of lorigerlimab and discontinuation of vobra duo development.
MacroGenics, Inc. reported that board member Jay Siegel, M.D. has informed the board that he will not stand for re-election as a Class I director at the company’s 2026 Annual Meeting of Stockholders. The company states that his decision is for personal reasons and not due to any disagreement regarding its operations, policies, or practices. MacroGenics thanks Dr. Siegel for his contributions to the company.
MacroGenics, Inc. reported that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers. Under this action, enrollment of new patients is paused, while existing participants may continue to receive the study drug.
The hold follows recent serious safety events in four patients, including Grade 4 thrombocytopenia in two cases, Grade 4 myocarditis in one case, and Grade 4 neutropenia with concurrent septic shock in one case that progressed to a Grade 5 event. To date, 41 participants have been dosed at 6 mg/kg every three weeks across platinum-resistant ovarian cancer and clear cell gynecologic cancer cohorts.
The LINNET trial uses a Simon two-stage design in platinum-resistant ovarian cancer, with a potential expansion from about 20 to 40 patients if a predefined activity threshold is reached, and includes up to 20 patients with clear cell gynecologic cancer. MacroGenics states it is committed to working closely with the FDA to resolve the partial hold and aims to resume enrollment as soon as conditions allow.
Armistice Capital and Steven Boyd reported beneficial ownership of 6,324,000 shares of MACROGENICS INC, representing 9.99% of the outstanding common stock as of 12/31/2025. The filing states Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises shared voting and dispositive power over those securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, is disclosed as potentially deemed to beneficially own the shares. The Master Fund is identified as the party with the economic right to dividends and sale proceeds.
MacroGenics Inc. senior vice president Ezio Bonvini reported new equity awards and a vesting event. On February 12, 2026, he acquired 31,250 restricted stock units (RSUs) and 187,500 employee stock options, with the options carrying a $1.71 exercise price per share.
On February 15, 2026, 16,665 RSUs were converted into common stock, increasing his directly held common shares to 152,232 before related tax withholding. To cover taxes, 6,433 common shares were disposed of at $1.71 per share, leaving 145,799 common shares owned directly after these transactions.
MacroGenics (MGNX) vice president Beth Ann Smith reported several equity compensation transactions. On February 12, 2026, she received a grant of 15,625 restricted stock units (RSUs) and 93,750 employee stock options with an exercise price of $1.71 per share.
On February 15, 2026, 1,095 RSUs converted into the same number of common shares, increasing her directly held common stock to 13,204 shares before tax settlement. To cover tax obligations, 423 common shares were withheld at $1.71 per share, leaving her with 12,781 common shares held directly after the transactions.
MacroGenics SVP and CFO James Karrels reported multiple equity compensation moves. On February 15, 2026, he exercised 14,999 restricted stock units, receiving the same number of common shares at an exercise price of $0. In a related tax-withholding transaction coded "F," 5,790 common shares were disposed of at $1.71 per share, leaving him with 206,037 common shares held directly.
Earlier, on February 12, 2026, he was granted an employee stock option for 150,000 shares at an exercise price of $1.71 per share, expiring on February 12, 2036. He also received a new grant of 25,000 restricted stock units, each RSU representing a right to one share, scheduled to vest 33% one year after grant and 33% each year thereafter.
MacroGenics executive Jeffrey Stuart Peters, Senior VP, General Counsel and Secretary, reported several equity compensation moves. On February 15, 2026, 13,332 restricted stock units were exercised into common shares, and 5,147 of those shares were withheld at $1.71 per share to cover tax obligations, leaving 31,105 common shares held directly.
Earlier, on February 12, 2026, Peters received a grant of 150,000 employee stock options with a $1.71 exercise price, expiring on February 12, 2036, and a separate grant of 25,000 restricted stock units. The RSUs are scheduled to vest in three equal annual installments, each representing the right to receive one share of MacroGenics common stock.